Research programme: anti-cancer immunotherapies - NouscomAlternative Names: Endovax; Exovax; Oncolytic antigenless vaccines; Personalized cancer vaccines
Latest Information Update: 28 Sep 2016
At a glance
- Originator Nouscom
- Class Antineoplastics; Cancer vaccines; Oncolytic viruses
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 Sep 2016 Early research in Cancer in Switzerland (unspecified route)
- 15 Mar 2016 Biomarkers information updated